Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Premenstrual Dysphoric Disorder (PMDD)

Ketamine for Premenstrual Dysphoric Disorder (PMDD)

1 paper and 0 clinical trials exploring ketamine as a treatment for premenstrual dysphoric disorder (pmdd).

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
Indication3-8% of women during their reproductive years.

Premenstrual Dysphoric Disorder (PMDD)

Premenstrual Dysphoric Disorder (PMDD) affects 5.5% of menstruating women with severe cyclical mood symptoms. This page includes an original exploratory research report investigating how women with PMDD use psilocybin, alongside evidence matrices and treatment landscape analysis.

Full Premenstrual Dysphoric Disorder (PMDD) profile

Academic Research

1 paper
Open Accessmeta

Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Womens

This preclinical review synthesises evidence on ketamine's rapid antidepressant effects in the female brain, emphasising how ovarian hormones modify its neurobiological actions. It highlights interpretative challenges in preclinical studies and proposes neuroinflammation as a key pathway mediating ketamine–estrogen interactions in women’s depression.

Published
January 18, 2022
Journal
Frontiers in Psychiatry
Authors
Brake, W. G., Gagne, C., Piot, A.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ketamine and Premenstrual Dysphoric Disorder (PMDD) yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ketamine papers Search all Premenstrual Dysphoric Disorder (PMDD) trials Full Ketamine profile Full Premenstrual Dysphoric Disorder (PMDD) profile